ArticleScientific reports2025
Nucleus YAP expression as a prognostic biomarker for local recurrence in eyelid sebaceous carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Eyelid sebaceous carcinoma (SbC) is a rare malignancy characterized by potentially aggressive behavior and a high local recurrence rate. This study aims to investigate the expression of nuclear YAP and its clinicopathological correlation in eyelid SbC. In the patients with eyelid SbC who had available tumor specimens, nuclear YAP and androgen receptor (AR) expression were assessed using immunohistochemistry staining, quantified by histochemical scoring (H-score). The primary outcome was local recurrence-free survival (LRFS). Additionally, distant recurrence-free survival, recurrence-free survival, and overall survival were evaluated. Among 47 patients, local recurrence occurred in 10 cases (21.3%), and distant recurrence was observed in 4 cases (8.5%) over a median follow-up period of 39.5 months. All local recurrence events were observed in the low nuclear YAP group (H-score ≤ 90), with a 5-year LRFS of 66.2% among 36 patients. Additionally, lower AR expression (H-score ≤ 50) was linked to a decreased 5-year LRFS of 59.4%, compared to 82.6% in the high AR expression group (Hazard ratio, 3.43; 95% CI, 0.96-12.20; p = 0.043). Lower nuclear YAP and AR expression appear to be associated with high local recurrence rates. Nuclear YAP expression may serve as a promising biomarker for prognosticating local recurrence in eyelid SbC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.